World Journal of Surgery

, Volume 27, Issue 6, pp 709–714 | Cite as

Role of Somatostatin in the Prevention of Pancreatic Stump-related Morbidity following Elective Pancreaticoduodenectomy in High-risk Patients and Elimination of Surgeon-related Factors: Prospective, Randomized, Controlled Trial

Original Scientific Reports


A prospective, randomized, controlled trial was performed to determine the efficacy of somatostatin in the prevention of pancreatic stump-related complications with elimination of surgeon-related factors in high-risk patients undergoing panceaticoduodenectomy. From August 1997 to December 2000, 54 patients, 28 men and 26 women, with age ranged from 32 to 89 years, were randomly assigned to somatostatin group (n = 27) or placebo group (n = 27). Ninety-four percent of the patients had pancreatic and periampullary lesions; 6% had secondary lesion involving the duodenum such as local recurrent colon carcinoma and renal cell carcinoma. These patients received either standard pancreaticoduodenectomy or pylorus-preserving pancreaticoduodenectomy. An experienced surgeon performed all operations in same fashion to minimize the surgical factor. A transanastomotic tube was inserted into the pancreatic duct for diversion of pancreatic juice in the pancreaticojejunostomy for a 3-weeks period postoperatively. Intravenous infusion of somatostatin was given at a dose of 250μg/hr in the somastotatin group and normal saline was given to the control group for 7 days postoperatively. There was one perioperative death in each group, resulting in a 3.7% mortality rate. In the somastotatin group, as compared to the placebo group, the incidence of overall morbidity and pancreatic stump related complications were significantly lower with a mean decrease of 50% pancreatic juice output and a slightly shorter duration of hospital stays. In conclusion, after excluding surgeon related factor, prophylactic use of somatostatin reduces the incidence and severity of pancreatic stump related complications in high-risk patients having pancreaticoduodenectomy via decreased secretion of pancreatic exocrine.


  1. 1.
    Whipple, AO 1941The rationale of radical surgery for cancer of the pancreas and ampullary regionAnn. Surg.114612615Google Scholar
  2. 2.
    Crist, DW, Sitzmann, JV, Cameron, JL 1987Improved hospital morbidity, mortality, and survival after the Whipple procedureAnn. Surg.206358365PubMedGoogle Scholar
  3. 3.
    Pellegrini, CA, Heck, CF, Raper, S,  et al. 1989An analysis of the reduced morbidity and mortality rates after pancreaticoduodenectomyArch. Surg.124778781PubMedGoogle Scholar
  4. 4.
    Yeo, CJ, Cameron, JL, Sohn, TA,  et al. 1997Six hundred fifty consecutive pancreaticoduodenectomy in the 1990s: pathology, complications, outcomesAnn. Surg.226248260CrossRefPubMedGoogle Scholar
  5. 5.
    Peter, JH, Carey, LC 1991Historical review of pancreaticoduodenectomyAm. J. Surg.16219225Google Scholar
  6. 6.
    Singh, SM, Longmire, WP, Reber, HA 1990Surgical palliation for pancreatic cancerAnn. Surg.212132139PubMedGoogle Scholar
  7. 7.
    Trede, M, Schwall, G 1988The complications of pancreatectomyAnn. Surg.2073947PubMedGoogle Scholar
  8. 8.
    Moosa, AR 1987Surgical treatment of chronic pancreatitis: an overviewBr. J. Surg.74661667PubMedGoogle Scholar
  9. 9.
    Schirmer, WJ, Rossi, RL, Braasch, JW 1991Common difficulties and complications in pancreatic surgerySurg. Clin. North Am.7113911417PubMedGoogle Scholar
  10. 10.
    Piorkowski, RJ, Blievernicht, SW, Lawrence, W,  et al. 1982Pancreatic and periampullary carcinoma: experience with 200 patients over a 12-year-periodAm. J. Surg.143189193PubMedGoogle Scholar
  11. 11.
    Carlo, VD, Chiesa, R, Pontiroli, AE,  et al. 1989Pancreatoduodenectomy with occlusion of the residual stump by neoprene injectionWorld J. Surg.13105111PubMedGoogle Scholar
  12. 12.
    Bassi, C, Falconi, M, Pederzoli, P 1994Role of somatostatin and somatostatin analogues in the treatment of gastrointestinal diseases: prevention of complications after pancreatic surgeryGut35S20S22PubMedGoogle Scholar
  13. 13.
    Jenkins, SA 1996Emerging Differences in the Therapeutic Efficacy of Somatostatin and Octreotide in Gastroenterology and SurgeryMediMedia Asian PublicationHong Kong14Google Scholar
  14. 14.
    Prinz, RA, Pickleman, J, Hoffman, JP 1988Treatment of pancreatic fistula with a somatostatin analogueAm. J. Surg.1553642PubMedGoogle Scholar
  15. 15.
    Petrin, P, Antoniutti, M, Zaramella, D,  et al. 1995Effect of octreotide acetate on pancreatic exocrine and endocrine functions after pancreaticoduodenal resectionEur. Surg. Res.27371378PubMedGoogle Scholar
  16. 16.
    Lin, PW, Lee, JC, Lee, PC,  et al. 1997A simple, secure, and universal pancreaticojejunostomy following pancreaticoduodenectomyHPB Surg.10305310PubMedGoogle Scholar
  17. 17.
    Hamanaka, Y, Suzuki, T 1994Total pancreatic duct drainage for leakproof pancreaticojejunostomySurgery1152226PubMedGoogle Scholar
  18. 18.
    Raptis, S, Schlegel, W, Lehmann, E,  et al. 1978Effects of somatostatin on the exocrine pancreas and the release of duodenal hormoneMetabolism.2713211328PubMedGoogle Scholar
  19. 19.
    Heintges, T, Luthen, R, Niederau, C 1994Inhibition of exocrine pancreas secretion by somatostatin and its analoguesDigestion5519Google Scholar
  20. 20.
    Klempa, J, Schwedes, U, Usadel, KH 1979Verhutung von postoperativen pankreatitischen koomplikationen nach duodenopankreatetomie durch somatostatinChirurgia (Bucur).50427431Google Scholar
  21. 21.
    Gouillat, C, Chipponi, J, Partensky, C,  et al. 1998Effects of somatostatin infusion on the pancreatic remnant secretions after pancreatoduodenectomyHepatogastroenterology.45198Google Scholar
  22. 22.
    Gouillat, C 1999Somatostatin for the prevention of complications following pancreaticoduodenectomyDigestion605963CrossRefPubMedGoogle Scholar
  23. 23.
    Büchler, M, Friess, H, Klempa, I,  et al. 1992Role of octreotide in the prevention of postoperative complications following pancreatic resectionAm. J. Surg.163125136PubMedGoogle Scholar
  24. 24.
    Montoris, M, Zago, M, Mosca, F,  et al. 1995Efficacy of octreotide in the prevention of pancreatic fistula after elective pancreatic resections: a prospective, controlled, randomized clinical trialSurgery1172631PubMedGoogle Scholar
  25. 25.
    Pederzoli, P, Bassi, C, Falconi, M,  et al. 1994Efficacy of octreotide in the prevention of complications after elective pancreatic surgeryBr. J. Surg.81265269PubMedGoogle Scholar
  26. 26.
    Habib, E, Elhadad, A, Fourtanier, G,  et al. 1998Place de l’octréotide dans la prévention des complications chirurgicales après pancréatectome. étude contrôlée multicentriqueAnn. Chir.52671672Google Scholar
  27. 27.
    Lowy, AM, Lee, TE, Pisters, PWT,  et al. 1997Prospective, randomized trial of octreotide to prevent pancreatic fistula after pancreaticoduodenectomyAnn. Surg.226632641CrossRefPubMedGoogle Scholar
  28. 28.
    Yeo, CJ, Cameron, JL, Lillemoe, KD,  et al. 2000Does prophylactic octreotide decrease the rates of pancreatic fistula and other complications after pancreaticoduodenectomy? Results of a prospective randomized placebo-controlled trialAnn. Surg.232419429CrossRefPubMedGoogle Scholar
  29. 29.
    Bartoli, FG, Arnone, GB, Ravera, G 1991Pancreatic fistula and relative mortality in malignant disease after pancreaticoduodenectomy. Review and statistical meta-analysis regarding 15 years of literatureAnticancer Res.1118311848PubMedGoogle Scholar
  30. 30.
    Friess, H, Bordih, K, Ebert, M,  et al. 1994Inhibition of pancreatic secretion under long-term octreotide treatment in humansDigestion551015PubMedGoogle Scholar
  31. 31.
    Londong, W, Angerer, M, Kutz, K,  et al. 1989Diminishing efficacy of octreotide (SMS 201-995) on gastric functions of healthy subjects during one-week administrationGastroenterology96713722PubMedGoogle Scholar
  32. 32.
    Ho, LT, Chen, RL, Chou, TY,  et al. 1986Pharmacokinetics and effects of intravenous infusion of somatostatin in normal subjects—a two-compartment open modelClin. Physiol. Biochem.4257267PubMedGoogle Scholar
  33. 33.
    Lin, PW, Lin, YJ 1999Prospective randomized comparison between pylorus-preserving and standard pancreaticoduodenectomyBr. J. Surg.86603607CrossRefPubMedGoogle Scholar
  34. 34.
    Yeo, CJ, Cameron, JL, Maher, MM,  et al. 1995A prospective randomized trial of pancreaticogastrostomy versus pancreaticojejunostomy after pancreaticoduodenectomyAnn. Surg.222580592PubMedGoogle Scholar
  35. 35.
    Hamanaka, Y, Nishihara, K, Hamasaki, T,  et al. 1996Pancreatic juice output after pancreaticoduodenectomy in relation to pancreatic consistency, duct size, and leakageSurgery119281287PubMedGoogle Scholar
  36. 36.
    Ishikawa, O, Ohigashi, H, Imaoka, S,  et al. 1991Concomitant benefit of preoperative irradiation in preventing pancreas fistula formation after pancreaticoduodenectomyArch. Surg.126885889PubMedGoogle Scholar
  37. 37.
    Van Hee, R, De Laet, I, Salgado, R,  et al. 1998The influence of somatostatin on postoperative outcome after elective pancreatic surgeryActa Chir. Belg.986265PubMedGoogle Scholar

Copyright information

© Société Internationale de Chirurgie 2003

Authors and Affiliations

  1. 1.Department of Surgery, Division of General SurgeryNational Cheng Kung UniversityTainanTaiwan
  2. 2.Institution of Clinical MedicineNational Cheng Kung UniversityTainanTaiwan

Personalised recommendations